Cut-off values of neonatal lysosomal storage disease-related enzymes detected by tandem mass spectrometry.
Child
Humans
Infant
Infant, Newborn
alpha-Galactosidase
alpha-Glucosidases
Fabry Disease
/ diagnosis
Galactosylceramides
Glucosylceramidase
Glycogen Storage Disease Type II
/ diagnosis
Iduronidase
Leukodystrophy, Globoid Cell
Lysosomal Storage Diseases
/ diagnosis
Neonatal Screening
Sphingomyelin Phosphodiesterase
Tandem Mass Spectrometry
/ methods
Cut value
Enzyme activity
Lysosomal storage disease
Neontal screening
Tandem mass spectrometry
Journal
Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
ISSN: 1008-9292
Titre abrégé: Zhejiang Da Xue Xue Bao Yi Xue Ban
Pays: China
ID NLM: 100927946
Informations de publication
Date de publication:
25 Jun 2022
25 Jun 2022
Historique:
pubmed:
25
4
2022
medline:
12
10
2022
entrez:
24
4
2022
Statut:
ppublish
Résumé
To establish cut-off values of lysosomal storage disease (LSD)-related enzymes by tandem mass spectrometry. A total of 26 689 newborns and 7 clinically confirmed LSD children underwent screening for LSDs (glycogen storage disease typeⅡ, Fabry disease, mucopolysaccharidosis type Ⅰ, Krabbe disease, Niemann-Pick disease A/B and Gaucher disease). The activities of LSD-related enzymes were detected by tandem mass spectrometry. The 20% of the median enzyme activity of each batch of acid β-glucocerebrosidase, acid sphingomyelinase, β-galactocerebroside, α- The enzyme activities of 7 clinically confirmed cases were all lower than the cut-off values. Among 26 689 newborns, 142 cases (0.53%) were suspected positive for LSDs, including 25 cases of β-galactocerebroside deficiency, 1 case of α- The established cut-off values of LSD-related enzyme activities detected by tandem mass spectrometry can be used for screening LSDs in neonates, and the enzyme activity would be affected by temperature and humidity.
Identifiants
pubmed: 35462462
doi: 10.3724/zdxbyxb-2022-0095
pmc: PMC9511489
doi:
Substances chimiques
alpha-Galactosidase
EC 3.2.1.22
alpha-Glucosidases
EC 3.2.1.20
galactocerebroside
0
Galactosylceramides
0
Glucosylceramidase
EC 3.2.1.45
Iduronidase
EC 3.2.1.76
Sphingomyelin Phosphodiesterase
EC 3.1.4.12
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
321-325Références
Genet Med. 2019 Mar;21(3):631-640
pubmed: 30093709
J Mol Med (Berl). 2020 Jul;98(7):931-946
pubmed: 32529345
Pediatrics. 2008 Jul;122(1):e39-45
pubmed: 18519449
Am J Med Genet A. 2009 May;149A(5):960-4
pubmed: 19396827
Zhonghua Er Ke Za Zhi. 2021 Jun 2;59(6):439-445
pubmed: 34102815
Int J Neonatal Screen. 2019 Mar;5(1):
pubmed: 30957052
Nat Rev Dis Primers. 2018 Oct 1;4(1):27
pubmed: 30275469
Mol Genet Metab. 2021 Sep-Oct;134(1-2):53-59
pubmed: 33832819
J Pediatr. 2017 Nov;190:130-135
pubmed: 28728811
Mol Genet Metab. 2016 Aug;118(4):304-9
pubmed: 27238910
J Inherit Metab Dis. 2018 Mar;41(2):209-219
pubmed: 29143201